GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invion Ltd (ASX:IVX) » Definitions » Capital Expenditure

Invion (ASX:IVX) Capital Expenditure : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Invion Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Invion's cash flow for capital expenditures for the six months ended in Dec. 2024 was A$0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Invion Capital Expenditure Historical Data

The historical data trend for Invion's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invion Capital Expenditure Chart

Invion Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -7.25 -2.58 -0.90

Invion Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -2.50 -0.90 - -

Invion Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invion Ltd (ASX:IVX) » Definitions » Capital Expenditure
Comparable Companies
ASX:EOF ASX:RGT ASX:EXL ASX:CAN ASX:BP8 ASX:PER ASX:ECS ASX:AGH ASX:NXS ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506
Traded in Other Exchanges
7C8:Germany
Address
692 High Street, East Kew, VIC, AUS, 3102
Website
https://www.inviongroup.com
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.

Invion Headlines

No Headlines